Understanding CAR T-cell therapy for blood cancers
Chimeric Antigen Receptor (CAR) T-cell therapy represents one of the most important advances in blood cancers over the past decade. This revolutionary highly personalised form of cellular immunotherapy uses a patient’s own immune cells and genetically modifies them to target and attack cancer cells with remarkable precision.
A new option for some blood cancers
For patients with specific types of relapsed or refractory lymphoma, acute lymphoblastic leukaemia (ALL) and multiple myeloma, CAR T-cell therapy has demonstrated positive results, achieving response rates previously unattainable with conventional treatments.
As clinical experience and research continue to grow, teams are working to make CAR T-cell therapy safer, more effective and more accessible. This includes improving how patients are selected for treatment, better managing side effects, and integrating CAR T-cell therapy into existing care pathways.
How CAR T-cell therapy works
CAR T-cell therapy begins by collecting a patient’s T-cells — a type of immune cell — from the blood. These cells are then sent to a specialised laboratory, where they are modified to help them recognise and attack cancer cells. Once the cells have been changed, they are called CAR T-cells. It can take a few weeks to make CAR T-cells. Sometimes patients may require other treatments to keep their cancer under control during CAR T-cell manufacturing.
Before CAR T-cell therapy is given, patients will usually receive a low dose of chemotherapy. This helps prepare the body so the CAR T-cells can work as effectively as possible once they are infused back into the bloodstream.
The cells are then infused back into the body through a quick, one-time IV infusion, where CAR T-cells act like a living drug, designed to recognise and attach to specific proteins on cancer cells, helping the immune system find and destroy them. These modified cells can also multiply inside the body, allowing them to continue targeting cancer cells over time and at scale.
Monitoring and managing side effects
Like many cancer treatments, CAR T-cell therapy can cause side effects, and patients are monitored closely throughout treatment and recovery. Common side effects can include infections, neurological symptoms, and a reaction called cytokine release syndrome (CRS).
CRS happens when the activated CAR T-cells trigger a strong immune response while attacking cancer cells. Symptoms can range from mild flu-like effects to more serious reactions, which is why close monitoring is important during and after treatment.
CAR T-cell therapy is delivered by experienced multidisciplinary teams in specially equipped centres that are trained to recognise and manage these side effects quickly. In most cases, side effects can be treated effectively and improve once managed appropriately.
Expanding access through clinical trials
CAR T-cell therapy is a highly specialised treatment that can be complex and costly. Because the cells are individually engineered for each patient, the process takes time and requires advanced laboratory and clinical expertise.
In Australia, access to CAR T-cell therapy is currently limited and is mainly available through the public health system for eligible patients with certain types of lymphoma and acute lymphoblastic leukaemia (ALL). Access for some patients with multiple myeloma is also continuing to evolve.
For many patients, access can still be affected by factors such as location, eligibility requirements and the stage of disease at which the treatment is offered.
Clinical trials are currently one of the key ways researchers and care teams are working to expand access to CAR T-cell therapy in Australia. These trials help explore how CAR T-cell therapy may be used earlier in treatment, as well as investigate newer therapies designed to improve effectiveness and reduce side effects.
Importantly, clinical trials are conducted under strict safety and ethical guidelines, helping ensure patients are closely monitored while contributing to ongoing research and future advances in care.
Treatment options at Icon
At Icon Cancer Centre South Brisbane, an ongoing clinical trial is exploring an innovative type of CAR T-cell therapy for certain types of lymphoma.
Unlike traditional CAR T-cell therapy, which uses a patient’s own immune cells, this treatment uses healthy donor T-cells. This approach may allow treatment to be prepared and delivered more quickly and, for some patients, may reduce the need for a hospital stay by enabling treatment in an outpatient setting.
The trial also includes an ultra-sensitive blood test designed to detect very small amounts of lymphoma that may remain after initial treatment, even when routine scans appear clear. This may help doctors identify patients at higher risk of the lymphoma returning earlier than current methods allow.
For patients who test positive, treatment with donor-derived CAR T-cells may be offered earlier in their care, before the lymphoma has a chance to relapse.
A hopeful future for cellular therapy
Around the world, CAR T-cell therapy is becoming an increasingly important treatment option for some blood cancers, with more therapies becoming available across different cancer types. In Australia, access to CAR T-cell therapy is also continuing to grow, including emerging treatment options for conditions such as multiple myeloma.
While access is still evolving, ongoing research, investment and clinical trials are helping more patients access these innovative therapies and supporting the development of safer, more effective models of care.
Clinical trials continue to play an important role in this progress. They can provide eligible patients with access to new and emerging CAR T-cell therapies while helping researchers and care teams better understand how these treatments can be used in the future.
As experience with CAR T-cell therapy continues to grow in Australia, there is increasing hope for patients with some hard-to-treat blood cancers. For many people, these advances are already helping create new treatment possibilities and improving outcomes that may once have seemed out of reach.
